Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Daiichi Sankyo acquires Plexxikon

Plexxikon Inc. today announced that its acquisition by Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company, has been successfully completed. Clearance under the Hart Scott Rodino Antitrust Improvements Act has been received. Under the terms of the deal, Plexxikon shareholders will receive $805 million up-front, with near-term milestone payments associated with the approval of PLX4032 totaling an additional $130 million.

4 Apr 2011

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark Pharmaceuticals announces the discovery and initiation of IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR 401, an anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark's Biologics Research Centre located in Switzerland.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Spondyloarthritis is a group of inflammatory conditions causing spine and joint pain and deformity, mostly in young men. Important updates on the epidemiology, diagnosis, and treatment of SpA are presented in the April issue of The American Journal of the Medical Sciences, official journal of the Southern Society for Clinical Investigation.

31 Mar 2011

Adeona reports $3,164,512 net revenue for 2010

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, reported its financial results for the year ended December 31, 2010, as well as updates since the beginning of the 4th quarter.

31 Mar 2011

Basic Yellow 1 dye extends lifespan in healthy nematodes, slows Alzheimer's disease-like pathology in worms

Basic Yellow 1, a dye used in neuroscience laboratories around the world to detect damaged protein in Alzheimer's disease, is a wonder drug for nematode worms. In a study appearing in the March 30, online edition of Nature, the dye, also known as Thioflavin T, (ThT) extended lifespan in healthy nematode worms by more than 50 percent and slowed the disease process in worms bred to mimic aspects of Alzheimer's.

31 Mar 2011

Glasgow Professor discusses about new approach for CML treatment at UK conference

Speaking at the UK National Stem Cell Network conference in York later today, Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia in which a small number of cancer cells persist despite effective therapy thus preventing cure.

31 Mar 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

Essential protein linked to TNF induced inflammation

SCIENTISTS have discovered an essential protein that controls inflammation induced by 'tumour necrosis factor' (TNF) - an important part of the body's defences against infection and a driver of cancer-associated inflammation, according to research published in Nature today (Wednesday).

31 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

USPTO grants composition-of-matter patent to Zalicus 'Synavive' product

Zalicus Inc. announced today that it has been granted a composition-of-matter patent by the U.S. Patent and Trademark office covering its product candidate Synavive.

30 Mar 2011

People with arthritis can benefit from exercise

An estimated 50 million adults in the United States suffer from arthritis. According to the Centers for Disease Control, one of the best ways to combat the onset of arthritis as well as to control pain and improve function is through exercise.

29 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

Immune system misinterprets threats and attacks body's own cells and tissue

Many chronic diseases are the result of the body's immune system mistakenly perceiving that the body is under attack from foreign bodies. A counterattack is then launched - an inflammatory response meant to vanquish the intruder. In reality, the immune system has misinterpreted the threat and is actually attacking the body's own cells and tissue.

24 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

AARDA report on American economic impact of AD released at congressional briefing

A new report by the American Autoimmune Related Diseases Association examining the economic impact of autoimmune disease on Americans, their families and the United States was released today at a congressional briefing as part of AARDA's 2011 National Autoimmune Diseases Awareness Month activities.

23 Mar 2011

Study finds IL-13 stimulates airway fibroblast invasion in asthma patients

Changes that occur in the airways of asthma patients are in part caused by the naturally occurring protein interleukin-13 which stimulates invasion of airway cells called fibroblasts, according to a study conducted by researchers at Duke University.

23 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Daiichi Sankyo acquires Plexxikon

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Adeona reports $3,164,512 net revenue for 2010

Basic Yellow 1 dye extends lifespan in healthy nematodes, slows Alzheimer's disease-like pathology in worms

Glasgow Professor discusses about new approach for CML treatment at UK conference

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Essential protein linked to TNF induced inflammation

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

USPTO grants composition-of-matter patent to Zalicus 'Synavive' product

People with arthritis can benefit from exercise

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Immune system misinterprets threats and attacks body's own cells and tissue

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

KaloBios commences KB004 Phase 1 trial in patients with leukemia

AARDA report on American economic impact of AD released at congressional briefing

Study finds IL-13 stimulates airway fibroblast invasion in asthma patients

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in